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Objective. Nonadherence to disease-modifying antirheumatic drugs (DMARDS) in rheumatoid arthritis (RA) and spondy-
loarthritis (SpA) results in increased disease activity and symptoms and poorer quality of life. We aimed to describe
patients’ attitudes and experiences of DMARDs in RA and SpA to inform strategies to improve medication adherence.
Methods. Databases (MEDLINE, Embase, PsycINFO, and CINAHL) were searched to January 2016. Thematic synthesis
was used to analyze the findings.
Results. From 56 studies involving 1,383 adult patients (RA [n = 1,149], SpA [n = 191], not specified [n = 43]), we identified 6
themes (with subthemes): intensifying disease identity (severity of sudden pharmacotherapy, signifying deteriorating health,
daunting lifelong therapy), distressing uncertainties and consequences (poisoning the body, doubting efficacy, conflicting
and confusing advice, prognostic uncertainty with changing treatment regimens), powerful social influences (swayed by
others’ experiences, partnering with physicians, maintaining roles, confidence in comprehensive and ongoing care, valuing
peer support), privilege and right of access to biologic agents (expensive medications must be better, right to receive a biologic
agent, fearing dispossession), maintaining control (complete ownership of decision, taking extreme risks, minimizing life-
style intrusion), and negotiating treatment expectations (miraculous recovery, mediocre benefit, reaching the end of the line).
Conclusion. Patients perceive DMARDs as strong medications with alarming side effects that intensify their disease iden-
tity. Trust and confidence in medical care, positive experiences with DMARDS among other patients, and an expectation
that medications will help maintain participation in life can motivate patients to use DMARDs. Creating a supportive envi-
ronment for patients to voice their concerns may improve treatment satisfaction, adherence, and health outcomes.
INTRODUCTION
Patients with rheumatoid arthritis and spondyloarthritis
(including ankylosing spondylitis, psoriatic arthritis, and
arthritis associated with inflammatory bowel disease) can
experience progressive joint damage, deformity, and disabil-
ity, which can limit functioning and impair quality of life
(1–4). Disease-modifying antirheumatic drugs (DMARDs)
are recommended first-line treatment, using a treat-to-target
strategy, particularly for rheumatoid arthritis and psoriatic
arthritis, with the aim of decreasing joint inflammation,
achieving remission, and preventing permanent damage
(5,6). Yet nonadherence to DMARDS remains a major clini-
cal challenge.
Supported by the Australian Government Research Training
Program Scholarship and Arthritis Australia Scholarship,
funded by The Allan and Beryl Stephens Grant from the Estate
of the Late Beryl Stephens. Dr. Tong’s work was supported by
a National Health and Medical Research Council Fellowship
(ID 1037162).
1Ayano Kelly, MBBS, FRACP: Canberra Rheumatology
and Australian National University, Canberra, Canberra
Hospital, Woden, Australian Capital Territory, and The
Children’s Hospital at Westmead, Westmead, New South
Wales, Australia; 2Kathleen Tymms, MBBS, FRACP: Can-
berra Rheumatology and Australian National University,
Canberra, and Canberra Hospital, Woden, Australian Capi-
tal Territory, Australia; 3David J. Tunnicliffe, MIPH,
Jonathan C. Craig, PhD, Allison Tong, PhD: The Children’s
Hospital at Westmead, Westmead, and Sydney School of
Public Health, The University of Sydney, Sydney, New
South Wales, Australia; 4Daniel Sumpton, MBBS, FRACP:
The Children’s Hospital at Westmead, Westmead, and Liver-
pool Hospital and Ingham Institute for Applied Medical
Research, Liverpool, New South Wales, Australia; 5Chan-
dima Perera, MBBS, FRACP: Canberra Hospital, Woden,
Australian Capital Territory, Australia; 6Kieran Fallon, MD,
Walter Abhayaratna, PhD: Canberra Hospital, Woden, and
Australian National University, Canberra, Australian
Capital Territory, Australia.
Address correspondence to Ayano Kelly, MBBS, FRACP,
Canberra Rheumatology, 9th Floor Canberra House, 40
Marcus Clarke Street, Canberra City, Australia 2601.
E-mail: Ayano.Kelly@anu.edu.au.
Submitted for publication March 5, 2017; accepted in
revised form July 18, 2017.
525
Arthritis Care & Research
Vol. 70, No. 4, April 2018, pp 525–532
DOI 10.1002/acr.23329
© 2017, The Authors. Arthritis Care & Research published by Wiley
Periodicals, Inc. on behalf of American College of Rheumatology.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.
Research estimates that only 66% of patients with rheu-
matoid arthritis are adherent to DMARDs (7). Nonadher-
ence is associated with disease flares, increased disability,
and health care costs in rheumatoid arthritis (8,9). The
patient-physician relationship, patients’ beliefs about med-
ications, knowledge about their disease, and self-efficacy
have been consistently identified as modifiable factors asso-
ciated with adherence in rheumatoid arthritis (7,10–12).
However, studies have not consistently demonstrated that
patient and treatment characteristics, including age, sex,
disease duration, number of medications, and side effects,
are associated with adherence (12,13).
International rheumatology guidelines emphasize shared
decision making in rheumatoid arthritis and spondy-
loarthritis (5,6,14). Shared decision making requires a com-
prehensive and detailed understanding of the patients’
values, priorities, and preferences, yet there is sparse
qualitative evidence for this approach in relation to
DMARDs. A thematic synthesis of multiple qualitative
studies can summarize and extend qualitative research in a
defined field (15). A systematic review of qualitative studies
has been performed in lay experiences of medicine taking
across multiple conditions (16). This study aims to describe
patients’ attitudes and experiences of DMARDs in rheuma-
toid arthritis and spondyloarthritis. The findings may be
used to develop strategies, models, and interventions to
improve treatment adherence, satisfaction, and health-
related outcomes.
MATERIALS AND METHODS
We followed the Enhancing Transparency of Reporting the
Synthesis of Qualitative Research framework (17). The sys-
tematic review does not require ethics approval by an insti-
tutional review board or ethical review board in accordance
with the policy of the authors’ institutions.
Selection criteria. Qualitative studies that reported the
perspectives and experiences of adults (ages ≥18 years) with
rheumatoid arthritis or spondyloarthritis taking DMARDs
were eligible. Observational epidemiologic studies, nonpri-
mary research articles (letters, commentaries, and reviews),
and non-English articles were excluded.
Data sources and searches. We searched MEDLINE,
Embase, CINAHL, and PsycINFO from database inception
to January 12, 2016 (see Supplementary Table 1, available
on the Arthritis Care & Research web site at http://online
library.wiley.com/doi/10.1002/acr.23329/abstract). We also
hand searched reference lists of relevant studies and
Figure 1. Search results. DMARDs = disease-modifying antirheumatic drugs.
Significance & Innovations
• Patients with rheumatoid arthritis/spondyloarthritis
equate disease-modifying antirheumatic drugs with
intensifying disease identity and distressing uncer-
tainties and consequences.
• Negotiating treatment expectations with a trust-
worthy, confident, and knowledgeable physician
may improve medication adherence.
• Patients wish to maintain control, are swayed by
social influences, and appreciate privileged biologic
agent access.
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searched Google Scholar for additional studies. We screened
the abstracts and examined the full text of potentially
relevant studies.
Comprehensiveness of reporting. We used a modified ver-
sion of the Consolidated Criteria for Reporting Qualitative
Health Research framework (COREQ) (18) to evaluate the
completeness of reporting of each interview study. Items
specific to the research team, methods, setting, analysis, and
interpretations were assessed. Three reviewers (AK, DJT,
DS) independently assessed each study and resolved dis-
agreements through a fourth reviewer (AT).
Synthesis of findings. We used thematic synthesis for data
analysis. We extracted all participant quotations and text
under the results and/or discussion/conclusion sections and
imported them into HyperResearch 2015 software, version
3.7.3. One author (AK) inductively identified preliminary
concepts. The preliminary coding framework was discussed
among authors (AK/KT/DJT/DS/AT) to ensure the codes
reflected the full range and depth of data. For each article,
AK performed line-by-line coding into themes and sub-
themes and refined them iteratively. Other authors (AK/DJT/
AT) identified conceptual links among themes to develop an
analytical thematic schema.
RESULTS
Literature search and study descriptions. From 2,113
citations, we included 56 studies involving 1,383 partici-
pants (Figure 1). Study characteristics are provided (Table 1
and Supplementary Table 2, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.23329/abstract). Participants were ages 26–86 years,
851 women (62%), 423 men (31%), and 109 sex unspecified
(8%). A total of 1,149 participants had rheumatoid arthritis
(83%), and 191 had spondyloarthritis (14%). The type of
arthritis was unspecified in 43 participants (3%). Disease
duration was <1 month to 49 years. Eighteen studies had
participants taking biologic DMARDs (32%), 3 studies had
conventional DMARDs (5%), 8 studies had both DMARD
groups (14%), and type of medication was unspecified in 27
studies (48%).
Comprehensiveness of reporting. The comprehensiveness
of reporting was variable, with interview studies (n = 51)
reporting 5–21 of the 26 items in the modified COREQ frame-
work (see Supplementary Table 3, available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.com/
doi/10.1002/acr.23329/abstract). Twenty-four studies (47%)
documented data saturation, and 44 studies (86%) specified
the use of researcher triangulation. Participant quotations
were provided in 49 studies (96%).
Synthesis. We identified 6 themes: intensifying disease
identity, distressing uncertainties and consequences, power-
ful social influences, privilege and right of access to biologic
agents, maintaining control, and negotiating treatment
expectations. The subthemes are described in the following
sections, with illustrative quotations in Supplementary
Table 4 (available on the Arthritis Care & Research web
site at http://onlinelibrary.wiley.com/doi/10.1002/acr.23329/
abstract). The conceptual links among themes are shown in
Figure 2.
Intensifying disease identity. “The more medication you
take. . .the more ill you feel. Maybe even more than you really
are” (19). This theme describes how DMARDs intensified the
patients’ feelings of being unwell, which occurred through-
out the patient’s journey from diagnosis, during DMARD
escalation and chronic maintenance therapy.
Severity of sudden pharmacotherapy. After being diag-
nosed with arthritis, some patients were shocked with
having to take medications for the first time and by how
strong the medications were. Patients who avoided medi-
cations previously could be particularly alarmed and view
DMARDs to be both unexpected and unwarranted. Some
chose not to start their medications because it would mean
they were seriously ill (19), or they were frightened by the
side effects of their first medication: “If this is the drug they
start with (methotrexate), what will be the side effects of the
next drug?” (19).
Table 1. Characteristics of included studies (n = 56)*
Study characteristics No. (%)
Year of publication
1990–2010 28 (50)
2011–2016 28 (50)
Region†
UK 27 (48)
US 5 (9)
Canada 5 (9)
Australia 2 (4)
Europe 16 (29)
Other‡ 2 (4)
Sample size
1–20 29 (52)
21–40 21 (38)
41–60 1 (2)
61–80 0 (0)
>80 3 (5)
Not reported 2 (4)
Type of arthritis
RA 41 (73)
RA and spondyloarthritis 7 (13)
Spondyloarthritis 4 (7)
Not reported 4 (7)
Type of DMARD
Biologic DMARD 18 (32)
Conventional and biologic DMARD 8 (14)
Conventional DMARD 3 (5)
Not reported 27 (48)
Method of data collection
Interviews 33 (59)
Focus groups 10 (18)
Interviews and focus groups 8 (14)
Other 5 (9)
* RA = rheumatoid arthritis; DMARD = disease-modifying anti-
rheumatic drug.
† One study was conducted in multiple countries.
‡ Ireland, Turkey (1 study each).
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Signifying deteriorating health. Being placed on increasing
numbers of medications was a sign of worsening illness and
created concerns about potential drug interactions. There-
fore, reducing medications could be an indicator of improv-
ing health and a primary health goal. When patients forgot to
take their medications because they felt well, they inter-
preted forgetting their medications as a sign of good health.
Daunting lifelong therapy. Patients despaired being
required to take lifelong medications, a reminder that
their arthritis was incurable. When some patients
stopped their medications, symptoms returned and their
ability to function decreased. This relapse made patients
feel physically dependent on medications and provoked
anxiety about long-term side effects.
Distressing uncertainties and consequences. “My ortho-
pedist said ‘arthritis patients actually have 2 diseases, that is
arthritis and methotrexate.’ I have always remembered that”
(20). This theme describes the difficulty and fear patients
experience due to uncertainty in relation to DMARD safety
and efficacy. Fears can be further heightened during times
of DMARD changes and from comments by other health
professionals.
Poisoning the body. DMARDs were perceived to be
strong, toxic (21) medications that could damage internal
organs, increase mortality, and increase the risk of having
cancer because of immune suppression. Patients were aware
that methotrexate is used to treat cancer, which made them
feel they were taking a “very, very strong drug” (22)
equivalent to chemotherapy. Patients expressed concern
about both conventional and biologic DMARDs. Some
reluctantly accepted the medication because of necessity:
“Hate it, but can’t do without it” (23). Others preferred
taking alternative medications that were perceived to be
natural and harmless.
Doubting efficacy. Sometimes patients felt vulnerable, as
if they were guinea pigs (24) trying one medication after
another. They waited in anxious anticipation to see if a new
medication would start working and found it difficult to
cope with any delay of demonstrable effect. If patients
were doing well, they questioned whether it was due to
the medication, or if their disease had naturally stopped
progressing.
Conflicting and confusing advice. Some patients felt they
received insufficient or contradictory information from
within and outside the rheumatology service. This lapse led
to confusion, mistrust, and heightened medication concerns.
For example, the patients’ pharmacist, family doctor, or
other specialists raised concerns about their DMARD. They
noted that the drug information leaflets contained more
information than provided by their physician.
Prognostic uncertainty with changing treatment regimens.
Patients were afraid of their arthritis worsening when they
switched or stopped their DMARDs. Even when patients
did well when taking their medications, they would worry
about returning “back to square one” (21). Some patients
taking biologic DMARDs noticed a dramatic worsening of
symptoms when they stopped their medications during
pregnancy or infections, or for surgery.
Powerful social influences. “I feel I have a good doctor,
and I feel that he was doing what was best for me personally.
If it wasn’t for the trust I have in my doctor, then no, I
wouldn’t have took it” (25). This theme describes how others,
Figure 2. Thematic schema. Patients equate medications with being ill and are terrified of side effects, uncertain of treatment efficacy,
and confused when receiving insufficient or conflicting medical advice. A trustworthy doctor, supportive health environment, and posi-
tive family influences and experiences of others can mitigate patient fears and improve their medication experience. Patients desire to
maintain control of their disease, their social roles, and their decision to take medications sometimes at extreme costs. Some patients
are pleasantly surprised by their treatment outcomes, while others are repeatedly disappointed. DMARDs = disease-modifying antirheu-
matic drugs.
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including family, friends, doctors, and nurses can strongly
influence the experience and perceptions of DMARDs in both
positive and negative ways.
Swayed by others’ experiences. Experiences of others
taking DMARDs could influence patients’ acceptance of
DMARDs. One patient’s mother developed gastrointestinal
hemorrhage, and another patient’s colleague took a day off
work after taking methotrexate, and the patient cited these
as reasons for never wanting to take methotrexate. In
contrast, some patients were motivated to take medica-
tions by family members with arthritis who accepted and
coped well with their DMARD, and from seeing older
family members who had developed deformities and
disability without DMARDs.
Partnering with physicians. Certain characteristics of the
physician and their communication could influence patients’
perceptions and attitudes toward DMARDs. Patients had con-
fidence in physicians who were knowledgeable and opti-
mistic, acknowledged their fears and needs, and provided a
range of treatment options. These physicians made patients
feel hopeful and secure in their treatment choices. Informa-
tion from their physician that was consistent with other
sources (e.g., internet, drug information leaflets) was regarded
as credible. Some patients valued shared decision making,
while others preferred to relinquish their decision to their
doctor who they trusted.
Maintaining roles. Being able to function in the family
role as a parent or grandparent could be the main reason for
patients to take DMARDs. Others wished to maintain work
roles and independence, or had a general goal to be healthy
and normal and live the life they had before (26). For some,
side effects from DMARDs impeded their ability to fulfil
these roles and would lead to DMARD discontinuation.
Confidence in comprehensive and ongoing care. Patients
felt secure with the frequency of followup in the biologic-
agents clinic and in the setting of clinical trials for
intensive conventional DMARD therapy. The practical
and psychosocial support that nurses provide during
regular biologic DMARD infusions and clinic visits and
over the telephone created positive experiences. In
contrast, some patients with ankylosing spondylitis found
followup in the biologic-agents clinic unnecessary and
inconvenient.
Valuing peer support. Patients valued the opportunity to
share experiences with others with the same illness while
receiving intravenous biologic-agent therapy. Some devel-
oped close friendships and considered their infusions to be a
social outing.
Privilege and right of access to biologic agents. “You sit
there and try and get every single drop out of, and then you
make sure that the syringe, you really press it and try to
squeeze the bit down to make sure you’ve got every drop. But
it does. . .I mean it is precious because it’s expensive” (27).
This theme describes unique attitudes and perceptions of
patients towards biologic DMARDs. The expense and re-
stricted access to these medications created a sense of
privilege for some, but could also invoke anger, guilt, and
fear of being denied or losing access.
Expensive medications must be better. Patients felt priv-
ileged to have access to biologic DMARDs as they were
“horribly expensive” (27), and they were careful not to waste
the medication when self-injecting.
Right to receive a biologic agent. Patients defended their
right to receive a biologic agent and were angered if they
did not meet the clinical requirements. They argued that
they paid national insurance, and that there was a long-
term economic benefit as surgery and hospitalizations
would be reduced. Patients who qualified for a biologic
agent felt guilty that others could not access these
medications.
Fearing dispossession. Once receiving biologic agents,
patients felt the medications were valued possessions and
were afraid that they would be deprived of them. Some
avoided telling the doctor or nurse of side effects, in case
they were taken off their biologic agent.
Maintaining control. “Let me have the choice that I want
to be treated aggressively. Don’t take that away from me”
(28). This theme describes the desire of patients to be in
control of the decision to take DMARDs and to choose a
DMARD based on life priorities. Patients also emphasized
the importance of maintaining disease control, occasionally
despite significant medication side effects.
Complete ownership of decision. Patients advocated
their right to make the final decision about taking biologic
and conventional DMARDs and wanted comprehensive
information, including alternative treatment options. They
urged physicians to be explicit about the potential effects of
DMARDs on the body, including recognition that DMARDs
were different from other medications that were perceived
to be safer.
Taking extreme risks. Patients wished to remain in control
of their disease and were willing to accept the risks of com-
plications such as organ damage or low platelet counts to
remain on their medications. Some ignored instructions to
stop their medication. When DMARDs were highly effective,
patients described them as something they would “kill for”
(29).
Minimizing lifestyle intrusion. Patients wanted to control
their choice of DMARD in order to minimize the impact
on their day-to-day life. They wanted information that
would better inform their decision making. For example,
they wanted to be informed of the need to limit their
alcohol intake, the timing of methotrexate dose to
decrease side effects at work, and the impact of their
DMARD on sexual function. Some patients preferred
subcutaneous to intravenous biologic agents, because they
could take the drug at home with minimal disruption to
their routine.
Negotiating treatment expectations. “I mean I was, you
know, really hoping against hope that it would work, having
been on, sort of, most of the other conventional drugs and
thinking well ‘If this doesn’t work, then what?’” (30). Patients’
emotional response to their DMARD varied widely between
joy, disappointment, and hopelessness, and depended on
their initial and ongoing expectations of their medications.
Miraculous recovery. Patients were surprised and delight-
ed if DMARDs exceeded their expectations and led to rapid
and dramatic improvements, particularly with tumor
necrosis factor inhibitors. Some patients felt “the healthiest
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I’ve been in years” (30) and described forgetting they had
arthritis. One patient described methotrexate as “the elixir of
life” (29). These DMARDs elevated their mood, self-esteem,
and relationships with their spouses and children.
Mediocre benefit. Other patients noted moderate improve-
ments with DMARDs but still had disease flares, needed to
use corticosteroids, and had functional limitations. Some
accepted this and hoped for future medical advances. Others
felt disappointed, as they were expecting an immediate and
pronounced response to DMARDs.
Reaching the end of the line. Failing multiple DMARDS
had a detrimental psychological and emotional impact on
patients who felt increasing desperation. Patients felt they
had reached the end of the line when given the option of
biologic-agent therapy and saw these DMARDs as their
last hope. They subsequently feared that if biologic agents
did not work, they had no other options.
DISCUSSION
Dependence on DMARDs exacerbated disease identity in
patients with rheumatoid arthritis and spondyloarthritis.
They were alarmed about potential side effects, uncertain of
treatment efficacy, and confused when they received con-
flicting medical advice. Concerns were alleviated through
trust, confidence, and support in their health environment
and positive experiences of family and friends. An immedi-
ate benefit or response to DMARDs was seen as a miracle,
whereas others felt disappointed and hopeless from failed
responses to DMARDs. The high cost and limited accessibil-
ity of biologic DMARDs increased their value.
Some experiences and perceptions were unique to biologic
DMARDs. Patients felt well, supported by frequent biologic-
agents clinic visits, nursing assistance, and peer support
during infusions. Extending these positive experiences to
conventional DMARD patients may improve their DMARD
experience. Biologic DMARD patients may also experience
rapid and dramatic treatment benefits and can feel privileged
to receive restricted medications. However, regardless of the
type of DMARD, arthritis, age, sex, and duration of disease,
patients had similar concerns of DMARD toxicity, loss of effi-
cacy, and desires to maintain control of their disease and
social roles. Additionally, patients taking either type of
DMARD desired to have control of the decision to take their
medications and reported experiences of mediocre benefits
or recurrent failures.
Our review has shown that patients believed DMARDs
increased mortality, risk of cancer, and organ damage,
despite evidence that cardiovascular disease and mortality
may be reduced with the use of methotrexate and biologic
DMARDs in rheumatoid arthritis (31,32). Explaining these
benefits may help increase acceptance and reduce fears of
long-term toxicity.
This study highlights the critical role of the patient-pro-
vider relationship in DMARD acceptance. By remaining
optimistic and knowledgeable, validating patients’ fears,
and understanding their practical needs, physicians can
foster a trusting and more successful therapeutic relation-
ship with their patient. Communicating potential benefits
and harms of medications by using examples of other
patients’ experiences may improve patients’ understanding.
Communication also needs to be consistent between
health professionals. Referring to reliable online
resources may help patients feel more confident in treat-
ment recommendations. A meta-analysis of 21 studies
involving training physicians in communication skills
found that all studies improved adherence (33). The use
of decision aids may also improve knowledge, reduce
decisional conflict, and increase participation in decision
making (34).
Clinicians are encouraged to follow international guide-
lines that recommend the early use of DMARDs, and escalat-
ing or changing treatment to aim for a target of remission or
low disease activity (5,6,14,35). However, patients can find
commencing DMARDs at the first consultation alarming,
and fear changes and escalations of therapy. This therapeu-
tic approach may be more acceptable if patients understand
that treating early and treating to target increases DMARD
efficacy and results in better long-term outcomes.
A structured approach may help the clinician discuss
DMARD use. The 5A approach (ask, assess, advise, assist,
arrange followup) to smoking cessation has been adapted to
guide brief counseling interventions targeting diet and exer-
cise (36,37). We suggest the following 5A approach to
address DMARD adherence (Figure 3). Ask about patients’
experiences of their DMARDs, their concerns (especially
those they may not mention, such as mortality, cancer, and
organ damage), and goals (which could be to take fewer
medications). Assess their willingness to take DMARDs.
Advise on the benefits of DMARDs (using examples, include
benefits on mortality, on maintaining roles, and control of
disease), options (including practical implications to life-
style), and communicate with optimism and consistency
(referring to reliable internet sources and drug information
leaflets). Assist patients taking DMARDs so they feel sup-
ported (including nursing, phone, and peer support).
Arrange adequate followup and continue to address the
above at every stage of their disease.
Similar barriers and facilitators to medicine taking have
been identified in other chronic conditions (16,38). The per-
ception of medicines as poison was identified in systemic
lupus erythematosus (39). Fear of medication dependence
Figure 3. Proposed 5A approach to addressing disease-modify-
ing antirheumatic (DMARD) drug use.
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and long-term side effects were identified with antihyper-
tensives and proton pump inhibitors (16). Medication non-
adherence as a means to deny illness was reported with
antiretroviral therapies and psychotropic medications (16).
Patients with cancer doubted the efficacy of their medica-
tions (40). Patients with HIV were positively influenced by
trustworthy health care providers and favorable experiences
of others, and were motivated to take medications to main-
tain social roles (41,42). Unique experiences in relation to
biologic DMARDs and specific ways to address barriers in
our population are derived from the qualitative studies in
our review.
Core themes relating to prescribed medications have been
described by Horne et al using a necessity-concerns construct
and by Azjen using the theory of planned behavior (43,44).
The necessity-concerns cognitive representation includes
beliefs about the necessity of medications, and beliefs about
concerns, including long-term toxicity, disruptive effects of
medication, and the danger of dependence. The theory of
planned behavior postulates 3 independent determinants of
intention and behavior. The first is attitude toward the behav-
ior and refers to a person’s favorable or unfavorable evalua-
tion of the behavior. The second is subjective norm and
refers to perceived social pressures to perform the behavior.
The third is perceived behavioral control and refers to the
perceived ease or difficulty of performing the behavior. Our
study adds a broad and in-depth understanding into the
beliefs of necessity and concerns, attitudes towards medica-
tion taking behavior, and the positive and negative social
pressures that influence adherence in rheumatoid arthritis
and spondyloarthritis.
Multiple researchers have independently assessed the
transparency of reporting and triangulated findings during
thematic analysis. Software was used to code the data to
ensure a systematic and reproducible methodology. Our
study has some limitations. While we provided contextual
details for the data (if reported), we acknowledge the poten-
tial for decontextualization of the original data. Most studies
were performed in high income countries with English-
speaking participants with rheumatoid arthritis. The type of
DMARD was not recorded in half the studies. This back-
ground highlights the need for qualitative studies to specify
the type of DMARD and explore perspectives in non-
English–speaking and spondyloarthritis patients. Successful
interventions to improve DMARD adherence are needed.
Exploring patients’ ideas on how to improve their experience
and perceptions of DMARDs may guide future interventions.
DMARDs are perceived as strong medications with fright-
ening side effects. However, trust and security in medical
care, positive DMARD experiences of others, and the ability
to maintain social roles can motivate patients to use
DMARDs. The physician is in a unique position to ac-
knowledge and address fears of DMARD toxicity and adjust
DMARD regimes to suit individual beliefs, lifestyles, and
goals. The 5A approach to DMARD adherence may help
structure discussions and combat barriers to medication
taking. Understanding, supporting, and remaining opti-
mistic for patients using these long-term medications can
improve DMARD experience, with an aim to promote qual-
ity use of medicines and maximize the benefit patients can
gain from their DMARDs.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it crit-
ically for important intellectual content, and all authors approved
the final version to be submitted for publication. Dr. Kelly had full
access to all of the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis.
Study conception and design. Kelly, Perera, Tong.
Acquisition of data. Kelly, Tunnicliffe, Sumpton, Tong.
Analysis and interpretation of data. Kelly, Tymms, Tunnicliffe,
Sumpton, Perera, Fallon, Craig, Abhayaratna, Tong.
REFERENCES
1. Pincus T, Callahan LF. What is the natural history of rheu-
matoid arthritis? Rheum Dis Clin North Am 1993;19:123–51.
2. Orchard T, Wordsworth B, Jewell D. Peripheral arthropa-
thies in inflammatory bowel disease: their articular distribu-
tion and natural history. Gut 1998;42:387–91.
3. Gladman D, Antoni C, Mease P, Clegg D, Nash P. Psoriatic
arthritis: epidemiology, clinical features, course, and out-
come. Ann Rheum Dis 2005;64 Suppl 2:ii14–7.
4. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing
spondylitis: an overview. Ann Rheum Dis 2002;61 Suppl 3:
iii8–18.
5. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR,
Sullivan MC, et al. 2015 American College of Rheumatology
guideline for the treatment of rheumatoid arthritis. Arthritis
Rheum 2016;68:1–26.
6. Gossec L, Smolen J, Ramiro S, de Wit M, Cutolo M, Dougados
M, et al. European League Against Rheumatism (EULAR) rec-
ommendations for the management of psoriatic arthritis with
pharmacological therapies: 2015 update. Ann Rheum Dis
2016;75:499–510.
7. Scheiman-Elazary A, Duan L, Shourt C, Agrawal H, Ellashof
D, Cameron-Hay M, et al. The rate of adherence to anti-
arthritis medications and associated factors among patients
with rheumatoid arthritis: a systematic literature review and
metaanalysis. J Rheumatol 2016;43:512–23.
8. Contreras-Ya~nez I, Cabiedes J, Rull-Gabayet M, Pascual-Ramos
V, De Leon SP. Inadequate therapy behavior is associated to
disease flares in patients with rheumatoid arthritis who have
achieved remission with disease-modifying antirheumatic drugs.
Am J Med Sci 2010;340:282–90.
9. Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T,
van den Heuvel W. Compliance to drug treatment of pa-
tients with rheumatoid arthritis: a 3 year longitudinal study.
J Rheumatol 1999;26:2114–22.
10. Pasma A, van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ.
Factors associated with adherence to pharmaceutical treat-
ment for rheumatoid arthritis patients: a systematic review.
Semin Arthritis Rheum 2013;43:18–28.
11. Salt E, Frazier S. Adherence to disease modifying anti-rheu-
matic drugs in rheumatoid arthritis patients: a narrative
review of the literature. Orthop Nurs 2010;29:260–75.
12. Van den Bemt BJ, Zwikker HE, Van Den Ende CH. Medication
adherence in patients with rheumatoid arthritis: a critical
appraisal of the existing literature. Expert Rev Clin Immunol
2012;8:337–51.
13. Pasma A, Van’t Spijker A, Luime JJ, Walter MJ, Busschbach
JJ, Hazes JM. Facilitators and barriers to adherence in the
initiation phase of disease-modifying antirheumatic drug
(DMARD) use in patients with arthritis who recently star-
ted their first DMARD treatment. J Rheumatol 2015;42:379–
85.
14. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester
G, Dougados M, et al. EULAR recommendations for the
management of rheumatoid arthritis with synthetic and bio-
logical disease-modifying antirheumatic drugs: 2013 update.
Ann Rheum Dis 2014;73:492–509.
15. Campbell R, Pound P, Pope C, Britten N, Pill R, Morgan M,
et al. Evaluating meta-ethnography: a synthesis of qualitative
research on lay experiences of diabetes and diabetes care.
Soc Sci Med 2003;56:671–84.
Qualitative Systematic Review of DMARDs in RA and SpA 531
16. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-
White G, et al. Resisting medicines: a synthesis of qualitative
studies of medicine taking. Soc Sci Med 2005;61:133–55.
17. Tong A, Flemming K, McInnes E, Oliver S, Craig J. Enhanc-
ing transparency in reporting the synthesis of qualitative
research: ENTREQ. BMC Med Res Methodol 2012;12:181.
18. Tong A, Sainsbury P, Craig J. Consolidated criteria for
reporting qualitative research (COREQ): a 32-item checklist
for interviews and focus groups. Int J Qual Health Care
2007;19:349–57.
19. Nota I, Drossaert CH, Taal E, van de Laar MA. Patients’ con-
siderations in the decision-making process of initiating dis-
ease-modifying antirheumatic drugs. Arthritis Care Res
(Hoboken) 2015;67:956–64.
20. Van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Kerstens PJ,
Dijkmans BA, et al. Discordant perspectives of rheumatolo-
gists and patients on COBRA combination therapy in rheuma-
toid arthritis. Rheumatology (Oxford) 2008;47:1571–6.
21. Goodacre LJ, Goodacre JA. Factors influencing the beliefs of
patients with rheumatoid arthritis regarding disease-modify-
ing medication. Rheumatology (Oxford) 2004;43:583–6.
22. Townsend A, Backman CL, Adam P, Li LC. A qualitative
interview study: patient accounts of medication use in early
rheumatoid arthritis from symptom onset to early postdiag-
nosis. BMJ Open 2013;3:e002164.
23. Van Tuyl LH, Hewlett S, Sadlonova M, Davis B, Flurey C,
Hoogland W, et al. The patient perspective on remission in
rheumatoid arthritis: ‘You’ve got limits, but you’re back to
being you again’. Ann Rheum Dis 2015;74:1004–10.
24. Fraenkel L, Seng EK, Cunningham M, Mattocks K. Under-
standing how patients (vs physicians) approach the decision
to escalate treatment: a proposed conceptual model. Rheuma-
tology (Oxford) 2015;54:278–85.
25. Salt E, Peden A. The complexity of the treatment: the deci-
sion-making process among women with rheumatoid arthri-
tis. Qual Health Res 2011;21:214–22.
26. Ahlmen M, Nordenski€old U, Archenholtz B, Thyberg I,
R€onnqvist R, Linden L, et al. Rheumatology outcomes: the
patient’s perspective. A multicentre focus group interview
study of Swedish rheumatoid arthritis patients. Rheumatol-
ogy (Oxford) 2005;44:105–10.
27. Sanderson T, Calnan M, Morris M, Richards P, Hewlett S.
The impact of patient-perceived restricted access to anti-
TNF therapy for rheumatoid arthritis: a qualitative study.
Musculoskeletal Care 2009;7:194–209.
28. Salt E, Rowles GD, Reed DB. Patient’s perception of quality
patient-provider communication. Orthop Nurs 2012;31:169–76.
29. Stamm TA, Machold KP, Smolen J, Prodinger B. Life stories
of people with rheumatoid arthritis who retired early: how
gender and other contextual factors shaped their everyday
activities, including paid work. Musculoskeletal Care 2010;
8:78–86.
30. Sanderson T, Calnan M, Morris M, Richards P, Hewlett S.
Shifting normalities: interactions of changing conceptions of
a normal life and the normalisation of symptoms in rheuma-
toid arthritis. Sociol Health Illn 2011;33:618–33.
31. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F.
Methotrexate and mortality in patients with rheumatoid
arthritis: a prospective study. Lancet 2002;359:1173–7.
32. De La Forest Divonne M, Gottenberg JE, Salliot C. Safety of
biologic DMARDs in RA patients in real life: a systematic
literature review and meta-analyses of biologic registers.
Joint Bone Spine 2017;84:133–40.
33. Zolnierek KB, DiMatteo MR. Physician communication and
patient adherence to treatment: a meta-analysis. Med Care
2009;47:826–34.
34. O’Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle V,
Llewellyn-Thomas H, et al. Decision aids for patients facing
health treatment or screening decisions: systematic review.
BMJ 1999;319:731–4.
35. Coates LC, Kavanaugh A, Ritchlin CT, GRAPPA Treatment
Guideline Committee. Systematic review of treatments for
psoriatic arthritis: 2014 update for the GRAPPA. J Rheuma-
tol 2014;41:2273–6.
36. Zwar N, Richmond R, Borland R, Stillman S, Cunningham
M, Litt J. Smoking cessation guidelines for Australian gen-
eral practice. Aust Fam Physician 2005;34:461–6.
37. Whitlock EP, Orleans CT, Pender N, Allan J. Evaluating pri-
mary care behavioral counseling interventions: an evidence-
based approach. Am J Prev Med 2002;22:267–84.
38. DiMatteo MR. Variations in patients’ adherence to medical
recommendations: a quantitative review of 50 years of re-
search. Med Care 2004;42:200–9.
39. Kumar K, Gordon C, Barry R, Shaw K, Horne R, Raza K. ‘It’s
like taking poison to kill poison but I have to get better’: a
qualitative study of beliefs about medicines in rheumatoid
arthritis and systemic lupus erythematosus patients of South
Asian origin. Lupus 2011;20:837–44.
40. Yagasaki K, Komatsu H, Takahashi T. Inner conflict in
patients receiving oral anticancer agents: a qualitative study.
BMJ Open 2015;5:e006699.
41. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH.
Adherence in antiretroviral therapy: a review of qualitative
studies. AIDS 2007;21:271–81.
42. Fagbami O, Oluwasanjo A, Fitzpatrick C, Fairchild R, Shin
A, Donato A. Factors supporting and inhibiting adherence
to HIV medication regimen in women: a qualitative analysis
of patient interviews. Open AIDS J 2015;9:45–50.
43. Horne R, Weinman J, Hankins M. The beliefs about medi-
cines questionnaire: the development and evaluation of a
new method for assessing the cognitive representation of
medication. Psychol Health 1999;14:1–24.
44. Ajzen I. From intentions to actions: a theory of planned behavior.
In: Action control. New York: Springer; 1985. p. 11–39.
532 Kelly et al
